Related Experiment Videos
A note on post-marketing safety study design to characterise time-dependent adverse events
Mamoru Narukawa1, Akifumi Yafune
1Division of Pharmaceutical Medicine, Kitasato University Graduate School, Tokyo, Japan. mnarukawa@hkg.odn.ne.jp
Purpose:
To investigate a suitable post-marketing safety study design, that is number of patients and duration of exposure, to well characterise adverse events (AEs) profiles under limited resources, fixed patient-months.
Methods:
A simulation study is conducted to investigate a suitable study design that can appropriately characterise the shape of the hazard function of AEs using the Weibull model. The reliability of the estimates is evaluated by referring their bias and mean squared error (MSE).
Results:
In general, patients should be followed for a longer period even if the number of patients is relatively small for characterising delayed AEs. Patients' drop-out affects the estimation and deteriorates its reliability. For AEs that are likely to occur soon after the exposure, a study with relatively shorter duration and large number of patients is preferable.
Conclusions:
It is important to evaluate statistically the appropriate study design in planning a safety study so that a good estimate of the hazard function would be obtained.
Related Concept Videos
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Assumptions of Survival Analysis
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Introduction To Survival Analysis
The primary goal of survival analysis is to estimate survival time—the time until a...
Bioavailability Study Design: Healthy Subjects Versus Patients
Clinical Trials
There are four phases in a clinical trial. A phase one...